Bharat Biotech's cholera vaccine successfully completes Phase-III trials
Bharat Biotech
International Ltd on Wednesday said its
oral Cholera Vaccine
Hillchol has successfully completed phase III clinical trials. The vaccine maker, in a press release, said it has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV.
Ogawa and Inaba are two serotypes of Vibrio cholerae O1, a bacterial species that causes cholera.
The findings of a double-blind, randomized phase III clinical trial evaluating the safety, immunogenicity, non-inferiority, and lot-to-lot consistency of the
Hillchol
oral cholera vaccine, compared to a comparator vaccine, were recently published in a journal. The study involved 1,800 participants, ranging from infants to adults, across 10 clinical sites in India, the release said.
Play Video
Pause
Skip Backward
Skip Forward
Unmute
Current Time
0:00
/
Duration
-:-:-
Loaded
:
0%
0:00:00
Stream Type
LIVE
Seek to live, currently behind live
LIVE
Remaining Time
-
-:-:-
1x
Playback Rate
Chapters
Chapters
Descriptions
descriptions off
, selected
Captions
captions settings
, opens captions settings dialog
captions off
, selected
Audio Track
default
, selected
Picture-in-Picture
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Text
Color
White
Black
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Text Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Opaque
Semi-Transparent
Transparent
Caption Area Background
Color
Black
White
Red
Green
Blue
Yellow
Magenta
Cyan
Opacity
Transparent
Semi-Transparent
Opaque
Font Size
50%
75%
100%
125%
150%
175%
200%
300%
400%
Text Edge Style
None
Raised
Depressed
Uniform
Drop shadow
Font Family
Proportional Sans-Serif
Monospace Sans-Serif
Proportional Serif
Monospace Serif
Casual
Script
Small Caps
Reset
restore all settings to the default values
Done
Close Modal Dialog
End of dialog window.
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Паста за почистване на бели обувки - PasteWhiteShoes
Murzel Shop
Купете сега
Undo
The participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years. They were randomized in a 3:1 ratio to receive either Hillchol or a comparator vaccine.
"This publication reaffirms our commitment to advancing vaccines built on rigorous research, thorough clinical trials, and reliable clinical data. It highlights our continued commitment to providing affordable, effective, and accessible vaccines for the populations who need them the most," said Krishna Ella, Executive Chairman of Bharat Biotech.
Live Events
Cholera is an acute diarrhoeal infection caused by ingesting food or water contaminated with Vibrio cholerae bacteria. Studies have estimated that 2.86 million cases and 95,000 deaths occur annually, the release further said.
Global demand for OCVs is close to 100 million doses a year, and given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol, it added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
an hour ago
- India Today
Appendix cancer on the rise among US millennials, new study finds
From breast and colon to stomach and pancreatic cancers, doctors are now seeing more cases in people under the age of 50. A new study adds another surprising cancer to that list: appendix it remains extremely rare, appendix cancer is steadily increasing, especially among younger generations - millennials and Gen Z in the US, according to new research published in the Annals of Internal study, led by researchers at Vanderbilt University Medical Centre, found that the number of people diagnosed with a type of appendix cancer called appendiceal adenocarcinoma (AA) has spiked in recent decades. Using data from the National Cancer Institute's SEER program, a comprehensive US cancer registry, researchers tracked cases between 1975 and analysed trends by birth cohort and discovered a clear pattern: people born after 1945 showed rising rates of appendix cancer, with the sharpest increases among those born in 1980 and 1985. A study found that the number of people diagnosed with a type of appendix cancer has spiked in recent decades. () advertisementIn fact, rates tripled for the 1980 birth cohort and quadrupled for the 1985 group when compared to people born in 1945."This suggests that something has changed in the environment or lifestyle of newer generations that's contributing to this rise,' said lead researcher Dr. Andreana Holowatyji, assistant professor of hematology and oncology at IS THIS HAPPENING?Unlike more common cancers, the causes of appendix cancer remain appendix, a small pouch attached to the large intestine, was long overlooked and often lumped in with colon cancer. But as diagnostic tools and cancer registries improve, it's become easier to track this specific type of the number of appendectomies (surgical removal of the appendix) has stayed the same over the years, the researchers rules out the possibility that more cancers are simply being discovered because more surgeries are being researchers believe that lifestyle and environmental factors may be to blame. Rising rates of obesity and metabolic disorders among younger generations are a known risk factor for several cancers. But Holowatyji says it's probably not just one thing. The appendix, a small pouch attached to the large intestine, was long overlooked and often lumped in with colon cancer. () "It's likely a combination of influences, things like diet, chemicals in the environment, or even changes in the gut microbiome, that could be triggering changes in the body's cells and increasing the risk," she told IT MATTERS FOR INDIA'S YOUNG ADULTSThough the study was based on US data, the findings carry relevance globally, including for Indian millennials and Gen is also seeing an increase in young people diagnosed with cancers traditionally considered diseases of older inactive for long periods, high intake of processed diets, exposure to pollution, and lack of early screening all play a appendix cancer is still so rare, awareness among doctors and the public is low. This means symptoms, like unexplained bloating, changes in bowel habits, or appetite loss, can easily be dismissed as minor digestive authors of the study are calling for more research into the causes of appendix cancer, especially in younger populations, increased awareness not just among medical professionals but also among young adults themselves. advertisement
The Hindu
an hour ago
- The Hindu
Who is Shubhanshu Shukla, the IAF officer heading to the ISS on Axiom-4 mission?
Group Captain Shubhanshu Shukla of the Indian Air Force is set to be the first Indian in over four decades to travel to space and board the International Space Station (ISS), with liftoff scheduled for June 11 as part of Axiom Space's Ax-4 mission. The flight, launching from NASA's Kennedy Space Center aboard a SpaceX Crew Dragon, marks a significant milestone in India's growing human spaceflight ambitions. Also Read: Axiom-4 mission: All eyes on weather conditions as agencies target June 11 launch The launch, originally scheduled for June 10 but delayed due to weather conditions, is now set for 5:30 p.m. IST on June 11 from Cape Canaveral, Florida. Shukla will serve as the mission pilot, joining Commander Peggy Whitson (U.S.), Sławosz Uznański (Poland), and Tibor Kapu (Hungary) for a two-week mission focused on scientific research and international collaboration. This mission is part of a privately funded commercial effort, with India reportedly investing over $60 million to facilitate Shukla's flight to the ISS. ISRO is spending ₹550 crore on the Axiom-4 mission. Who is Shubhanshu Shukla? Born on October 10, 1985, in Lucknow, Shubhanshu Shukla completed his schooling from City Montessori School before joining the National Defence Academy. Commissioned into the Indian Air Force in 2006, he has accumulated over 2,000 hours of flying time on a wide range of aircraft including the Su-30 MKI, MiG-29, Jaguar, and Dornier-228. He holds an in Aerospace Engineering from the Indian Institute of Science, Bengaluru. Mr. Shukla was one of four officers selected in 2019 for ISRO's Gaganyaan human spaceflight programme. He underwent extensive training at Russia's Gagarin Cosmonaut Training Centre and ISRO's Astronaut Training Facility in Bengaluru. Earlier this year, he was announced as part of the Axiom-4 crew, in what is seen as a crucial step ahead of India's crewed space missions under Gaganyaan. Shukla, who goes by the nickname 'Shux', will be the second Indian to travel to space, 41 years after his idol Rakesh Sharma undertook a spaceflight in 1984 onboard the erstwhile Soviet Union's Soyuz spacecraft for an eight-day stay in orbit. Earlier this week, the crew addressed a press conference to give an update on the training ahead of the launch. 'This is not just my journey; this is the journey of 1.4 billion Indians. Even if this story can change one life or inspire one young person, it will be a success,' Mr. Shukla said. What is Axiom-4 mission? The Axiom-4 crew is expected to stay aboard the ISS for 14 to 21 days, conducting over 60 experiments in partnership with 31 countries. These range from biomedical research to Earth observation and materials science. Some of the experiments were developed with input from ISRO, offering India valuable scientific and operational insights ahead of the Gaganyaan mission, now expected in 2027. The Ax-4 mission will 'realize the return' to human spaceflight for India, Poland, and Hungary, with each nation's first government-sponsored flight in more than 40 years. While Ax-4 marks these countries' second human spaceflight mission in history, it will be the first time all three nations will execute a mission on board the International Space Station. This historic mission underscores how Axiom Space is redefining the pathway to low-Earth orbit and elevating national space programs globally.
New Indian Express
an hour ago
- New Indian Express
ICRISAT's new recipe makes tur dal taste better for farmers
HYDERABAD: Pigeon pea (known as kandi in Telugu and tur dal in Hindi) will now be cultivated in all seasons, including summer, following the development of a new cultivar by the International Crops Research Institute for the Semi-Arid Tropics (ICRISAT). The variety, ICPV 25444, is the first of its kind that can withstand high temperatures of up to 45°C and matures in just 125 days. According to ICRISAT researchers, pigeon pea cultivation has so far been restricted to specific seasons, primarily kharif, due to its sensitivity to photoperiod and temperature. The development of ICPV 25444, currently under field trials, marks a shift towards transforming this pulse into an all-season crop, offering new possibilities for Indian farmers. Dr Prakash Gangashetty, senior scientist in pigeon pea breeding at ICRISAT and part of the team responsible for the development, said, 'Pigeon pea is mainly grown in the kharif season. The country's requirement is nearly five million tonnes, but production has remained between 2.5 and three million tonnes.'
